$88.40 -$0.50 (-0.6%)

04:00 PM EST on 11/21/19

Incyte Corp (NASDAQ:INCY)

CAPS Rating: 3 out of 5

The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.

Current Price $88.40 Mkt Cap $19.1B
Open $89.50 P/E Ratio 47.03
Prev. Close $88.90 Div. (Yield) $0.00 (0.0%)
Daily Range $87.85 - $89.70 Volume 1,033,257
52-Wk Range $62.03 - $90.00 Avg. Daily Vol. 1,018,186

Caps

How do you think NASDAQ:INCY will perform against the market?

Add Stock to CAPS Watchlist

All Players

304 Outperform
37 Underperform
 

All-Star Players

70 Outperform
9 Underperform
 

Wall Street

17 Outperform
1 Underperform
 

Top NASDAQ:INCY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (85.15)
Submitted April 25, 2017

The setback on its RA drug with LLY offers an attractive entry into this intriguing drug developer. With Jakafi sales growth (and profitability) and the potential for a best-in-class IDO-inhibitor (with data coming up), I think this company deserves… More

zzlangerhans (99.78)
Submitted June 07, 2012

Jakafi revenue of 21M for Q1 was respectable but that number will like have to go much higher before Incyte will come close to neutralizing their hefty quarterly burn. Aside from preliminary data from the phase IIb trial of LY3009104 in rheumatoid… More

NASDAQ:INCY VS S&P 500 (SPY)

Fools bullish on NASDAQ:INCY are also bullish on:

Fools bearish on NASDAQ:INCY are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about INCY.

Recs

0
Member Avatar TMFBlacknGold (93.89) Submitted: 10/17/2018 11:35:29 AM : Outperform Start Price: $21.23 NASDAQ:INCY Score: +212.12

Glad I jumped on the JAK inhibitor train in 2013 with a green thumb, otherwise this pick would be a huge loss. +1 for long-term investing. What happens from here? As of this pitch (October 2018) shares have lost 40% of their value in the last 12 months. That continues the long slide triggered by some disasters in the pipeline in the last few years. The business is still strong -- growing and profitable -- but I see why investors have adjusted the market cap to $13 billion. Is that still a little juiced? Who knows. I'm content riding this pick out for now.

Recs

0
Member Avatar TMFBigFrog (92.88) Submitted: 10/4/2018 9:03:21 AM : Outperform Start Price: $69.76 NASDAQ:INCY Score: +19.85

Relatively reasonable risk/reward profile in a crazy industry.

Recs

0
Member Avatar TurksFan (41.88) Submitted: 4/7/2018 8:43:26 AM : Outperform Start Price: $64.57 NASDAQ:INCY Score: +17.86

Starting my research into biotechs

Leaderboard

Find the members with the highest scoring picks in INCY.

Score Leader

sara1985

sara1985 (98.41) Score: +3,376.94

The Score Leader is the player with the highest score across all their picks in INCY.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
sara1985 98.41 4/6/2009 Outperform NS $2.35 +3,653.19% +276.25% +3,376.94 0 Comment
dkelleher83 31.66 3/26/2009 Outperform NS $2.44 +3,514.75% +279.92% +3,234.84 0 Comment
emmtom1 < 20 5/27/2009 Outperform 1Y $2.94 +2,900.51% +242.84% +2,657.67 0 Comment
TaooaT 95.57 5/11/2009 Outperform 3Y $3.03 +2,810.89% +241.95% +2,568.94 0 Comment
baylesbrothers < 20 6/22/2009 Outperform 5Y $3.27 +2,597.25% +242.19% +2,355.05 0 Comment
rffoss 66.43 5/12/2009 Outperform 3Y $3.33 +2,548.65% +242.22% +2,306.42 0 Comment
ovrsxdunderpaid 38.87 6/12/2009 Outperform 5Y $3.35 +2,532.84% +232.17% +2,300.66 0 Comment
want2retirenow 67.08 6/1/2009 Outperform 5Y $3.35 +2,532.84% +234.77% +2,298.06 0 Comment
slimjim2005007 < 20 6/10/2009 Outperform 3M $3.42 +2,478.95% +231.18% +2,247.77 1 Comment
FoolInNY 26.90 6/4/2009 Outperform 5Y $3.54 +2,391.53% +232.02% +2,159.51 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for INCY.